FDA details timeframe of MS drug Tysabri's risks
(Reuters)
Biotechnology News
Reuters - The brain infection risk from Biogen Idec's multiple sclerosis drug Tysabri appears highest during the third year of treatment, U.S. health officials said in an updated warning released on Friday.
Source: Yahoo! News: Biotechnology News